Sector News

Roche buys France’s Trophos in 470 million euro deal

January 16, 2015
Life sciences
Roche has hit the acquisition trail to buy France’s Trophos in a deal that could be worth 470 million euros.
 
Trophos, a privately-held biotech based in Marseille, France, has developed olesoxime, which is being developed for spinal muscular atrophy – a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children. Results from a Phase II trial have shown a beneficial effect on the maintenance of neuromuscular function and a reduction in medical complications associated with the disease.
 
Under the terms of the agreement, Trophos’ shareholders will receive 120 million euros upfront and up to 350 million euros based on achievement of predetermined milestones.
 
Roche’s chief medical officer Sandra Horning said “we will build on the work done by Trophos and the French Muscular Dystrophy Association to advance the development of olesoxime and to bring it to people who live with this devastating condition as quickly as possible”. The compound has orphan drug status on both sides of the Atlantic.
 
The deal rounds off a busy week for Roche, which has paid over $1 billion to acquire a majority stake in molecular information company Foundation Medicine. The Swiss giant licensed an early-stage treatment for antibiotic resistance from Japan’s Meiji Seika Pharma and Fedora of Canada in a deal that could be worth $750 million.
 
By Kevin Grogan
 
Source: Pharma Times

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend